DGIdb - PLAU Gene Record

PLAU 5328 Druggable Genome

Alternate Names:

5328
PLASMINOGEN ACTIVATOR, UROKINASE
PLAU
ATF
BDPLT5
QPD
UPA
URK
u-PA
191840
9052
ENSG00000122861
OTTHUMG00000018494
P00749
UROK_HUMAN
UROKINASE-TYPE PLASMINOGEN ACTIVATOR LONG CHAIN A
UROKINASE-TYPE PLASMINOGEN ACTIVATOR PRECURSOR (EC 3.4.21.73) (UPA) (U-PLASMINOGEN ACTIVATOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P00749]
UROKINASE-TYPE PLASMINOGEN ACTIVATOR
T17758

Gene Info:

Uniprot Status	Swiss-Prot
Interpro Name	Peptidase S1/S6, chymotrypsin/Hap
Uniprot Evidence	1: Evidence at protein level
Human Readable Name	DRUGGABLE GENOME
Human Readable Name	PROTEASE
Interpro Short Name	Peptidase_S1_S6
Interpro Acc	IPR001254
Interpro Type	Domain
Target Class	Enzymes
Target Subclass	EC:3.4.21.73
Gene Biotype	PROTEIN_CODING

(6 More Sources)

Gene Categories: Category Details

CELL SURFACE
PROTEASE
DRUGGABLE GENOME
ENZYME

Publications:

Rosselli et al., 1992, Developmental regulation of Sertoli cell aromatase activity and plasminogen activator production by hormones, retinoids and the testicular paracrine factor, PModS., Biol. Reprod.
Garbisa et al., 1997, Suppression of metastatic potential and up-regulation of gelatinases and uPA in LLC by protracted in vivo treatment with dacarbazine or razoxane., Int. J. Cancer
Heikkilä et al., 2002, Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines., Anticancer Drugs
Go et al., 1997, Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro., Clin. Exp. Metastasis
Freeman et al., 1990, Urokinase- and tissue-type plasminogen activators are suppressed by cortisol in the involuting prostate of castrated rats., Biochem. J.
Yagyu et al., 2006, Enhanced spontaneous metastasis in bikunin-deficient mice., Int. J. Cancer
Gyetko et al., 1988, Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester., J. Immunol.
Wielockx et al., 2003, Serine proteases of the fibrinolysis pathway are not involved in lethal hepatitis and fibrinogen breakdown induced by tumor necrosis factor., Cytokine
Bell, 2002, Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics., Rev Cardiovasc Med
Gamberi et al., Identification of markers of possible prognostic value in 57 giant cell tumors of bone., Oncol. Rep.
Chang et al., Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells., Cell Commun. Adhes.
Zhang et al., 2003, Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy., J. Am. Soc. Nephrol.
Ziegler et al., 1990, Ca2+ potentiates cAMP-dependent expression of urokinase-type plasminogen activator gene through a calmodulin- and protein kinase C-independent mechanism., J. Biol. Chem.
Aguirre Ghiso et al., 1998, Secretion of urokinase and metalloproteinase-9 induced by staurosporine is dependent on a tyrosine kinase pathway in mammary tumor cells., Int. J. Cancer
Dunn et al., 2001, Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase., Cancer Res.
Zhang et al., 2005, [Changes of coagulation and fibrinolysis system in bronchoalveolar lavage fluid in lung fibrosis]., Beijing Da Xue Xue Bao
Levenson et al., 1998, Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor., Br. J. Cancer
Luparello et al., 2003, PTHrP [67-86] regulates the expression of stress proteins in breast cancer cells inducing modifications in urokinase-plasminogen activator and MMP-1 expression., J. Cell. Sci.
Xing et al., 1999, Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation., Int. J. Cancer
Henic et al., 2006, EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor., Gynecol. Oncol.
Armstead et al., 2005, Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury., Brain Res. Dev. Brain Res.
Andrews et al., 2005, Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells., Breast Cancer Res. Treat.

UPAMOSTAT PLAU

Interaction Score: 4.76

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Mesupron, WX-671

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD
UROKINASE PLAU

Interaction Score: 2.77

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name urokinase for injection,Kinlytic

Novel drug target Established target

PMIDs:
12824001 12556741 12579271 12745435 12707394

Sources:
TdgClinicalTrial TTD
SARUPLASE PLAU

Interaction Score: 2.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
IRESSA PLAU

Interaction Score: 2.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16263158

Sources:
NCI
BLEOMYCIN PLAU

Interaction Score: 2.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16224526

Sources:
NCI
RAZOXANE PLAU

Interaction Score: 2.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9378540

Sources:
NCI
AMEDIPLASE PLAU

Interaction Score: 1.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
ZOLEDRONIC ACID PLAU

Interaction Score: 0.79

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11984068

Sources:
NCI
ALENDRONIC ACID PLAU

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11984068

Sources:
NCI
IONOMYCIN PLAU

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1701176

Sources:
NCI
ANTIBIOTIC PLAU

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12724357

Sources:
NCI
CLODRONIC ACID PLAU

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11984068

Sources:
NCI
FILGRASTIM PLAU

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16331631

Sources:
NCI
CALCITRIOL PLAU

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3139763

Sources:
NCI
CARMUSTINE PLAU

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9219734

Sources:
NCI
DACARBAZINE PLAU

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9378540

Sources:
NCI
RETINOL PLAU

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1576255

Sources:
NCI
GELDANAMYCIN PLAU

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12724357

Sources:
NCI
PAPAVERINE PLAU

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16099300

Sources:
NCI
ESTRADIOL PLAU

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9662256

Sources:
NCI
AZACITIDINE PLAU

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10209960

Sources:
NCI
VERAPAMIL PLAU

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9579573

Sources:
NCI
HYDROCORTISONE PLAU

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2115769

Sources:
NCI
SIROLIMUS PLAU

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11245436

Sources:
NCI
CELECOXIB PLAU

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16172791

Sources:
NCI
CISPLATIN PLAU

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9219734

Sources:
NCI

Ensembl: ENSG00000122861
- Version: 101_38
Alternate Names:

PLAU Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
HopkinsGroom: P00749
- Version: 11-September-2012
Alternate Names:

5328 Entrez Gene Id

P00749 Uniprot Accession

UROK_HUMAN Uniprot Id

Gene Info:

Uniprot Status Swiss-Prot

Interpro Name Peptidase S1/S6, chymotrypsin/Hap

Uniprot Evidence 1: Evidence at protein level

Gene Categories:

PROTEASE, DRUGGABLE GENOME

Publications:

RussLampel: ENSG00000122861

Version: 26-July-2011

Alternate Names:

ENSG00000122861 Ensembl Gene Id

UROKINASE-TYPE PLASMINOGEN ACTIVATOR PRECURSOR (EC 3.4.21.73) (UPA) (U-PLASMINOGEN ACTIVATOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P00749] Description

PLAU Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

TdgClinicalTrial: P00749
- Version: January-2014
Alternate Names:

PLAU Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:3.4.21.73

Publications:

NCI: PLAU

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Rosselli et al., 1992, Developmental regulation of Sertoli cell aromatase activity and plasminogen activator production by hormones, retinoids and the testicular paracrine factor, PModS., Biol. Reprod.

Heikkilä et al., 2002, Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines., Anticancer Drugs

Go et al., 1997, Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro., Clin. Exp. Metastasis

HingoraniCasas: ENSG00000122861
- Version: 31-May-2017
Alternate Names:

ENSG00000122861 Gene Symbol

PLAU Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
dGene: PLAU
- Version: 27-Jun-2013
Alternate Names:

5328 Gene ID

ATF dGene Synonym

BDPLT5 dGene Synonym

Gene Info:

Gene Categories:

PROTEASE

Publications:
TTD: Urokinase-type plasminogen activator
- Version: 2020.06.01
Alternate Names:

PLAU TTD Gene Abbreviation

T17758 TTD Target ID

Gene Info:

Publications:
Pharos: PLAU
- Version: 01-February-2022
Alternate Names:

Urokinase-type plasminogen activator Gene Name

P00749 UniProt ID

Gene Info:

Gene Categories:

ENZYME

Publications:
GO: PLAU
- Version: 01-February-2022
Alternate Names:

Gene Info:

Gene Categories:

CELL SURFACE

Publications:

Trial Name	Mesupron, WX-671
Novel drug target	Established target

Trial Name	urokinase for injection,Kinlytic
Novel drug target	Established target

5328	Entrez Gene Id
P00749	Uniprot Accession
UROK_HUMAN	Uniprot Id

ENSG00000122861	Ensembl Gene Id
UROKINASE-TYPE PLASMINOGEN ACTIVATOR PRECURSOR (EC 3.4.21.73) (UPA) (U-PLASMINOGEN ACTIVATOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P00749]	Description
PLAU	Display Id

Urokinase-type plasminogen activator	Gene Name
P00749	UniProt ID

PLAU Gene Record

PLAU 5328 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Mesupron, WX-671 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial TTD

Interaction Types & Directionality: n/a

Interaction Info: Trial Name urokinase for injection,Kinlytic Novel drug target Established target

PMIDs: 12824001 12556741 12579271 12745435 12707394

Sources: TdgClinicalTrial TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16263158

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16224526

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9378540

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11984068

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11984068

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1701176

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12724357

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11984068

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16331631

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 3139763

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9219734

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9378540

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1576255

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12724357

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Mesupron, WX-671

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name urokinase for injection,Kinlytic

Novel drug target Established target

PMIDs:
12824001 12556741 12579271 12745435 12707394

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
16263158

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16224526

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9378540

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
11984068

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11984068

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1701176

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12724357

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11984068

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16331631

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
3139763

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9219734

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9378540

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1576255

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12724357

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16099300

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9662256

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10209960

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9579573

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
2115769

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11245436

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16172791

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9219734

Sources:
NCI